Sales and marketing expenses increased to approximately $2,809,000 for 2005 from approximately $1,857,000 for the prior year, reflecting the Company's expanded sales and marketing efforts in the pulp & paper market.
The net loss for 2005 was approximately $10,515,000, or $0.48 per share (diluted). This compares to a net loss for 2004 of approximately $6,080,000, or $0.37 per share (diluted).
At December 31, 2005, Dyadic reported cash and cash equivalents of approximately $12,150,000 versus approximately $20,511,000 at December 31, 2004.
Dyadic International Inc is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1.
Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries.
Dyadic intends to utilize its patented enabling and proprietary platform technologies on its own behalf and under license to business collaborators for the discovery, development and manufacture of biological products from genes to produce targeted protein products for diverse markets.
marketing@alchempro.com
